Gilead announced that the FDA has approved the supplemental new drug application, or sNDA, for Vemlidy 25 mg tablets as a once-daily treatment for chronic hepatitis B virus, or HBV, infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
